Forest Laboratories and Almirall have submitted a new drug application to the FDA for their inhaled aclidinium bromide, a dry powder long-acting inhaled antimuscarinic agent for the treatment of COPD. Forest has licensed the US rights to the product; Almirall retains the rights elsewhere.
The aclidinium bromide formulation is delivered via a multi-dose DPI and will be sold under the name Eklira.
Read the Forest and Almirall press release.
published on
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
October 28, 2026: Webinar: From Guidance to Practice: Navigating Revised FDA PSGs for Inhaled Products, online
November 10-November 11: Rescon Europe 2026, Porto, Portugal
